Scientists find LSD may stimulate anti-tumor immune activity against colorectal cancer through serotonin receptor signaling in preclinical research

LSD is being investigated for a possible anti-cancer role after preclinical findings suggested it can activate parts of the immune system involved in fighting colorectal tumors. The central claim links LSD to serotonin receptor signaling that may help strengthen anti-tumor responses rather than acting only through psychedelic effects. Colorectal cancer provides the disease context, and the reported mechanism appears to involve immune modulation in ways that could make tumor growth harder to sustain. That makes the finding notable beyond psychedelic medicine's usual focus on mental health, because it points toward oncology and immunology as adjacent areas of interest. The significance remains early-stage and likely limited to laboratory or animal research rather than established human treatment. Any therapeutic relevance would depend on replication, dose clarification, safety assessment, and determining whether anti-cancer effects can be separated from psychoactive effects in clinical settings.